Tumor imaging of colo-rectal carcinoma with an anti-CEA monoclonal antibody

M. Gasparini, M. Ripamonti, E. Seregni, E. Regalia, G. L. Buraggi

Research output: Contribution to journalArticle

Abstract

A 131I-labelled anti-CEA monoclonal antibody (MAb) (FO23C5) was used in a preclinical in vivo study in an animal model and in a clinical study in patients with colo-rectal carcinoma. Preliminary screening on different tissue was performed with immunoperoxidase staining, which showed a good specificity of the antibody for gastric and colo-rectal carcinoma. Initially immunoscintigraphy was performed as a pilot study at the National Cancer Institute of Milan on 51 patients with 64 localizations of colorectal cancer. Serial scans were performed after injection of 2 radioactive reagents, namely 131I and 111In. In vivo pharmacokinetics of the compound were studied. High sensitivity (80%) and high specificity were obtained in detecting local recurrences and abdominal metastases whereas a low positivity rate was obtained in detecting liver metastases. Our data were confirmed by preliminary results of the multicentric trial organized by the Italian National Research Council on 300 patients with about 700 localizations of CEA producing tumors.

Original languageEnglish
Pages (from-to)81-84
Number of pages4
JournalInternational Journal of Cancer
Volume41
Issue numberSUPPL. 2
Publication statusPublished - 1988

Fingerprint

Monoclonal Antibodies
Carcinoma
Neoplasm Metastasis
Neoplasms
Antibody Specificity
National Cancer Institute (U.S.)
Colorectal Neoplasms
Stomach
Animal Models
Pharmacokinetics
Staining and Labeling
Recurrence
Injections
Liver
FO23C5 monoclonal antibody
Clinical Studies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tumor imaging of colo-rectal carcinoma with an anti-CEA monoclonal antibody. / Gasparini, M.; Ripamonti, M.; Seregni, E.; Regalia, E.; Buraggi, G. L.

In: International Journal of Cancer, Vol. 41, No. SUPPL. 2, 1988, p. 81-84.

Research output: Contribution to journalArticle

@article{c04a7235903b45b7bded59bd8aaeb2b2,
title = "Tumor imaging of colo-rectal carcinoma with an anti-CEA monoclonal antibody",
abstract = "A 131I-labelled anti-CEA monoclonal antibody (MAb) (FO23C5) was used in a preclinical in vivo study in an animal model and in a clinical study in patients with colo-rectal carcinoma. Preliminary screening on different tissue was performed with immunoperoxidase staining, which showed a good specificity of the antibody for gastric and colo-rectal carcinoma. Initially immunoscintigraphy was performed as a pilot study at the National Cancer Institute of Milan on 51 patients with 64 localizations of colorectal cancer. Serial scans were performed after injection of 2 radioactive reagents, namely 131I and 111In. In vivo pharmacokinetics of the compound were studied. High sensitivity (80{\%}) and high specificity were obtained in detecting local recurrences and abdominal metastases whereas a low positivity rate was obtained in detecting liver metastases. Our data were confirmed by preliminary results of the multicentric trial organized by the Italian National Research Council on 300 patients with about 700 localizations of CEA producing tumors.",
author = "M. Gasparini and M. Ripamonti and E. Seregni and E. Regalia and Buraggi, {G. L.}",
year = "1988",
language = "English",
volume = "41",
pages = "81--84",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Tumor imaging of colo-rectal carcinoma with an anti-CEA monoclonal antibody

AU - Gasparini, M.

AU - Ripamonti, M.

AU - Seregni, E.

AU - Regalia, E.

AU - Buraggi, G. L.

PY - 1988

Y1 - 1988

N2 - A 131I-labelled anti-CEA monoclonal antibody (MAb) (FO23C5) was used in a preclinical in vivo study in an animal model and in a clinical study in patients with colo-rectal carcinoma. Preliminary screening on different tissue was performed with immunoperoxidase staining, which showed a good specificity of the antibody for gastric and colo-rectal carcinoma. Initially immunoscintigraphy was performed as a pilot study at the National Cancer Institute of Milan on 51 patients with 64 localizations of colorectal cancer. Serial scans were performed after injection of 2 radioactive reagents, namely 131I and 111In. In vivo pharmacokinetics of the compound were studied. High sensitivity (80%) and high specificity were obtained in detecting local recurrences and abdominal metastases whereas a low positivity rate was obtained in detecting liver metastases. Our data were confirmed by preliminary results of the multicentric trial organized by the Italian National Research Council on 300 patients with about 700 localizations of CEA producing tumors.

AB - A 131I-labelled anti-CEA monoclonal antibody (MAb) (FO23C5) was used in a preclinical in vivo study in an animal model and in a clinical study in patients with colo-rectal carcinoma. Preliminary screening on different tissue was performed with immunoperoxidase staining, which showed a good specificity of the antibody for gastric and colo-rectal carcinoma. Initially immunoscintigraphy was performed as a pilot study at the National Cancer Institute of Milan on 51 patients with 64 localizations of colorectal cancer. Serial scans were performed after injection of 2 radioactive reagents, namely 131I and 111In. In vivo pharmacokinetics of the compound were studied. High sensitivity (80%) and high specificity were obtained in detecting local recurrences and abdominal metastases whereas a low positivity rate was obtained in detecting liver metastases. Our data were confirmed by preliminary results of the multicentric trial organized by the Italian National Research Council on 300 patients with about 700 localizations of CEA producing tumors.

UR - http://www.scopus.com/inward/record.url?scp=0023672455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023672455&partnerID=8YFLogxK

M3 - Article

C2 - 3162449

VL - 41

SP - 81

EP - 84

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - SUPPL. 2

ER -